Predict your next investment

THE WAVE TALK company logo
ELECTRONICS | Electronic test, measurement & monitoring
thewavetalk.com

See what CB Insights has to offer

Founded Year

2016

Stage

Corporate Minority | Alive

Total Raised

$7.55M

Last Raised

$1.8M | 7 mos ago

About THE WAVE TALK

THE WAVE TALK develops biosensors that analyze laser-induced waves to instantly detect the presence of micro-organisms in liquid, with applications for hospitals, factories, and home appliances.

THE WAVE TALK Headquarter Location

T337, Jinri Hall 193, Munji-ro, Yueseong-gu

Daejeon, 34051,

South Korea

Latest THE WAVE TALK News

THE.WAVE.TALK Raises US$2M in Funding

Apr 8, 2020

THE.WAVE.TALK , a Seoul, South Korea-based developer of live bacteria sensing and IoT water turbidity test technology, raised USD2m in funding. This brought its accumulated total to approximately US$6m in funding. Existing investors include Bluepoint Partners, Naver, EstechPharma, and LB Investment (previously LG fund). The company intends to use the funds to continue to develop its product, constructing a big data network that automatically measures the water quality of ordinary households through an IoT sensor, and expand into the global market. Led by CEO Kim Young-dug Kim, THE.WAVE.TALK has developed its own live bacteria sensing and IoT water turbidity test technology, which will allow for speedy antibiotic susceptibility testing (AST) and minimum inhibitory concentration (MIC) testing at hospitals (in developing countries) with equipment that costs just several hundreds of USD. Currently, the company is working with four major local governments to complete a testbed by June that utilizes an IoT sensor to automatically test the most important factor of water quality, in turbidity, in homes. THE.WAVE.TALK will also be working on gaining certification from Good Manufacturing Practice (GMP) and Korea’s Ministry of Food and Drug Safety on antibiotic inspection equipment (such as “Bacometer AI” that can diagnose urinary tract infection in under 3 hours, and AST/MIC in under 6 hours). FinSMEs

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

THE WAVE TALK Patents

THE WAVE TALK has filed 14 patents.

The 3 most popular patent topics include:

  • Microbiology
  • Spectroscopy
  • Armidale-class patrol boats
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/17/2019

10/26/2021

Spectroscopy, Armidale-class patrol boats, Microbiology, Microbial population biology, Luminescence

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

5/17/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

10/26/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Spectroscopy, Armidale-class patrol boats, Microbiology, Microbial population biology, Luminescence

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

THE WAVE TALK Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

THE WAVE TALK Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.